Dare Bioscience, Inc. DARE 深 沪
已收盘 02-06 16:00:00 美东时间
1.69
+0.010
+0.60%
华盛通- 最 高1.75
- 今 开1.73
- 成交量 6.48万股
- 最 低 1.69
- 昨 收 1.68
- 总市值 2414.88万
- 52周最高 9.19
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 1.61
- 委 比 84.69%
- 总股本 1428.92万
- 历史最高 76.44
- 量 比 0.56
- 振 幅 3.57%
- 历史最低 1.61
- 每 手 1
- 风险率 0.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Daré Bioscience Launches First Evidence-Backed Topical Sildenafil Cream For Women
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical cream shown in clinical studies to increase genital blood flow in
2025-12-10 21:08
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
2025-12-03 09:58
HC Wainwright & Co. Reiterates Buy on Dare Bioscience, Maintains $12 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $12 price target.
2025-12-02 19:57
Daré Bioscience Regains Full Rights To Ovaprene As Bayer Terminates License Agreement
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that all rights to
2025-12-01 21:10
Daré Bioscience Receives About $3.6M Payment Under Existing Grant Agreement With Gates Foundation
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has received
2025-11-24 21:04
电话会总结 ｜ Daré Bioscience(DARE)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Daré Bioscience业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金状况：** 截至第三季度末，公司现金及现金等价物约为2,300万美元，营运资金约为380万美元。 **融资活动：** 第三季度通过普通股销售获得约1,870万美元净收益，同时收到730万美元的政府资助资金。 **费用支出：** - 一般管理费用（G&A）为250万美元 - 研发费用（R&D）为120万美元 ## 2. 财务指标变化 **费用同比变化：** - 一般管理费用同比增长25%（从2024年第三季度的200万美元增至250万美元），主要由于
2025-11-14 12:19
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates
Earnings Call Insights: Daré Bioscience (DARE) Q3 2025 Management View CEO Sabrina Johnson stated that "Daré is at an inflection point. The third quarter of 2025 reflects the continued acceleration of...
2025-11-14 08:42
Dare Bioscience Q3 EPS $(0.28) Beats $(0.39) Estimate, Sales $2.262K Miss $9.750K Estimate
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.39) by 27.27 percent. This is a 49.09 percent increase over losses of $(0.55) per share from
2025-11-14 05:02
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
Daré Bioscience Secures Gates Foundation Contract Worth Up To $300K To Conduct A Strategic Landscape Review Of Organizations With Capabilities Relevant To Contraceptive Product Development
Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced a contract with the
2025-11-03 21:14
